| Species |
Human |
| Protein Construction |
NKG2A&CD94 (Arg100-Leu233(NKG2A)&Ser34-Ile179(CD94))_x000D_
Accession # P26715-1(NKG2A)&Q13241-1(CD94) |
mFc (IgG1) |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized NKG2A&CD94 mFc Chimera, Human at 1 μg/ml (100μl/well) on the plate can bind AntiNKG2A Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
56.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-90 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies. |
| Synonyms |
CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
